Abstract
British Journal of Clinical PharmacologyVolume 72, Issue 1 p. 182-182 Free Access Erratum This article corrects the following: A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours Xuexin He, Su Li, He Huang, Zhiming Li, Likun Chen, Sheng Ye, Jiajia Huang, Jing Zhan, Tongyu Lin, Volume 71Issue 6British Journal of Clinical Pharmacology pages: 860-870 First Published online: May 12, 2011 First published: 09 June 2011 https://doi.org/10.1111/j.1365-2125.2011.04030.xAboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat REFERENCE 1 He X, Li S, Huang H, Li Z, Chen L, Ye S, Huang J, Zhan J and Lin T. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours Br J Clin Pharmacol 2011; 71: 860– 70. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar In the above paper 1 the authors have identified the following error: CA4P should be CA4 on line 7 of the Results section in the abstract on page 860. The sentence should read as For CA4, at 50 mg m−2, mean (SD) peak plasma concentration (Cmax) was 0.99 (0.33) µm, area under the curve from time zero to time of last quantifiable concentration (AUC(0,t)) was 1.42 (0.30) µm h and terminal elimination half-life (t1/2) was 1.81 (0.61) h. At 65 mg m−2, Cmax was 1.73 (0.62) µm, AUC(0,t) was 3.19 (1.47) µm h and t1/2 was 1.90 (0.61) h. Volume72, Issue1July 2011Pages 182-182 ReferencesRelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
